Russell Investments Group Ltd. Buys 11,667 Shares of Charles River Laboratories International, Inc. $CRL

Russell Investments Group Ltd. increased its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 59.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 31,175 shares of the medical research company’s stock after purchasing an additional 11,667 shares during the period. Russell Investments Group Ltd. owned approximately 0.06% of Charles River Laboratories International worth $4,730,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Brooklyn Investment Group lifted its holdings in shares of Charles River Laboratories International by 93.5% in the first quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 86 shares in the last quarter. Cromwell Holdings LLC raised its position in Charles River Laboratories International by 542.9% in the 2nd quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock valued at $27,000 after buying an additional 152 shares during the last quarter. Neo Ivy Capital Management bought a new stake in Charles River Laboratories International in the 2nd quarter valued at approximately $29,000. Allworth Financial LP boosted its position in Charles River Laboratories International by 172.7% during the 2nd quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock worth $45,000 after acquiring an additional 190 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd bought a new position in shares of Charles River Laboratories International during the 2nd quarter worth approximately $56,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on CRL shares. Jefferies Financial Group raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $142.00 to $195.00 in a research report on Tuesday, September 9th. Morgan Stanley set a $185.00 price target on shares of Charles River Laboratories International in a research report on Monday, December 1st. Barclays raised their price objective on Charles River Laboratories International from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. Argus set a $200.00 target price on Charles River Laboratories International in a report on Monday, November 17th. Finally, William Blair raised Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a research report on Monday, October 6th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $190.86.

Charles River Laboratories International Stock Up 0.2%

Shares of CRL stock opened at $184.49 on Friday. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $202.72. The stock has a market cap of $9.08 billion, a price-to-earnings ratio of -118.26, a PEG ratio of 6.52 and a beta of 1.63. The firm’s 50-day moving average is $174.84 and its 200-day moving average is $161.56. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.10 and a current ratio of 1.37.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share for the quarter, topping analysts’ consensus estimates of $2.32 by $0.11. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $990.43 million. Charles River Laboratories International had a positive return on equity of 15.78% and a negative net margin of 2.07%.The business’s revenue was down .5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.59 earnings per share. Sell-side analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).